Prot #GS-US-337-0108: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Trea

Project: Research project

Project Details

StatusFinished
Effective start/end date5/1/1312/31/16

Funding

  • PRA Health Sciences (GS-US-337-0108)
  • Gilead Sciences, Inc. (GS-US-337-0108)